Quantcast
Last updated on April 18, 2014 at 12:57 EDT

Latest Sanofi Stories

2014-01-13 04:20:50

TARRYTOWN, N.Y., Jan. 13, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has amended and restated its investor agreement with Sanofi (EURONEXT: SAN and NYSE: SNY), which was originally entered into in December 2007. Under the terms of the amended and restated agreement, Sanofi retains its right to acquire up to 30% of Regeneron's outstanding common stock and Class A stock and gains the right to nominate a single independent director to...

2014-01-08 12:28:46

SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life Sciences Industry and Principal of Beacon Street Advisors, brings to the company significant experience of the biotechnology industry, through a number of positions as a Senior Executive...

2014-01-08 08:28:31

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 8, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Express Scripts Holding Company (NASDAQ: ESRX), Sanofi SA (ADR) (NYSE: SNY), Agilent Technologies Inc. (NYSE: A) and Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH). Today's readers may access these reports free of charge - including full price targets,...

FDA Rejects French MS Drug
2013-12-30 15:18:55

Brett Smith for redOrbit.com - Your Universe Online The Food and Drug Administration (FDA) has rejected French drugmaker Sanofi’s multiple sclerosis (MS) treatment called Lemtrada, the company announced on Monday. The rejection is considered a serious blow to the company, which had the drug recently approved by other regulatory bodies. The FDA did not approve the drug on the grounds that the Sanofi-owned developer Genzyme had not demonstrated that its medical benefits offset its...

2013-12-19 00:20:33

Collaboration represents the first time the ACC's PINNACLE Registry Research Alliance will be used for clinical trial recruitment PARIS and TARRYTOWN, N.Y., Dec. 19, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an innovative collaboration with the American College of Cardiology (ACC) focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein...

2013-12-12 23:28:53

Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December 12, 2013 Spartan Bioscience today announced the start of a 150-patient study of personalized medicine for cardiac stent patients in Poland, Hungary, and Lithuania. The study is sponsored by the Medical University of Warsaw, and is entitled “Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During...

2013-12-12 20:24:22

WAYNE, Pa., Dec. 12, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of purchasers of Sanofi contingent value rights (NASDAQ: GCVRZ) ("CVRs" or "shares") between March 6, 2012 and November 7, 2013, inclusive (the "Class Period"). (Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO ) For more information regarding this class action suit,...

2013-12-11 23:22:41

ChinaMarketResearchReports.com adds “Global and China Insulin Industry Report, 2013-2017” latest report to its store. Dallas, TX (PRWEB) December 11, 2013 As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing...

2013-12-10 23:20:12

Reportbuyer.com just published a new market research report: Biosimilar Opportunities in an Evolving Market. London (PRWEB) December 10, 2013 Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two...

2013-12-09 12:25:18

Developing approaches for involving patients in drug development BRIDGEWATER, N.J., Dec. 9, 2013 /PRNewswire/ -- Today, Sanofi US launched its second Partners in Patient Health (PiPH) Innovation Challenge: Collaborate | Innovate, which will award $100,000 to the winning team. This year's theme is "Co-Creating for Breakthroughs: Moving toward a collaborative research and development ecosystem." The Challenge calls on non-profit patient, provider and professional associations to partner with...